At the 2015 annual meeting of the American Society of Hemtology (ASH), potentially practice-changing novelties were published, which reform our way of thinking about sickle cell disease. Three highlighted studies were mentioned, two of these present promising new insights for managing the disease in children, the third demonstrates a new oral therapy.

(BELG J HEMATOL 2016; 7(1): 53–4)